Considerations for the Role of the Pharmacist in Managing Patients on Eculizumab for Hematopoietic Stem Cell Transplantation–Related Thrombotic Microangiopathy
Restricted accessLetterFirst published online May, 2023
Considerations for the Role of the Pharmacist in Managing Patients on Eculizumab for Hematopoietic Stem Cell Transplantation–Related Thrombotic Microangiopathy
Soliris (eculizumab) package insert.Cheshire, CT: Alexion Pharmaceuticals Inc.; Nov 2020.
2.
JodeleSDandoyCEDanziger-IsakovL, et al. Terminal complement blockade after hematopoietic stem cell transplantation is safe without meningococcal vaccination. Biol Blood Marrow Transplant. 2016;22(7):1337-1340. doi:10.1016/j.bbmt.2016.03.032.
3.
JodeleSFukudaTVinksA, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2014;20(4):518-525. doi:10.1016/j.bbmt.2013.12.565.
4.
JodeleSLaskinBLDandoyCE, et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev. 2015;29(3):191-204. doi:10.1016/j.blre.2014.11.001.
5.
BohlSRKuchenbauerFvon HarsdorfS, et al. Thrombotic microangiopathy after allogeneic stem cell transplantation: a comparison of eculizumab therapy and conventional therapy. Biol Blood Marrow Transplant. 2017;23(12):2172-2177. doi:10.1016/j.bbmt.2017.08.019.
6.
JodeleSDandoyCELaneA, et al. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood. 2020;135(13):1049-1057. doi:10.1182/blood.2019004218.
7.
JodeleSFukudaTMizunoK, et al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(2):307-315. doi:10.1016/j.bbmt.2015.10.002.
